Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 654-658

  Schraml, Peter ^a   Von Teichman, Adriana ^a   Mihic Probst, Daniela ^a   Simcock, Mathew ^b   Ochsenbein, Adrian ^c   Dummer, Reinhard ^a   Michielin, Olivier ^d   Seifert, Bettina ^e   Schläppi, Marc ^f   Moch, Holger ^a   Von Moos, Roger ^g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f Canton Hospital St Gallen   (Switzerland)

^g Medical Oncology   (Switzerland)

Author keywords

Bevacizumab; Melanoma; O6 methylguanine DNA methyltransferase; Temozolomide

Indexed keywords

BEVACIZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DNA METHYLATION; EPIGENOMICS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME;

EID: 84863477650     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1826     Document Type: Article

References (26)

1. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
2. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
3. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
4. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010.
5. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745, 2006. (Pubitemid 46630937)
6. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745-2751, 1999. (Pubitemid 29415231)
7. Stevens MF, Hickman JA, Langdon SP, et al: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[ 5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852, 1987. (Pubitemid 18018717)
8. Tsang LL, Quarterman CP, Gescher A and Slack JA: Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 27: 342-346, 1991.
9. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005. (Pubitemid 40349502)
10. Ingold B, Schraml P, Heppner FL and Moch H: Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS One 4: e4775, 2009.
11. Newlands ES, Blackledge GR, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291, 1992.
12. Bleehen NM, Newlands ES, Lee SM, et al: Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910-913, 1995.
13. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166, 2000. (Pubitemid 30036349)
14. Patel PM, Suciu S, Mortier L, et al: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47: 1476-1483, 2011.
15. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003.
16. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191, 2004. (Pubitemid 41095154)
17. von Moos R, Seifert B, Simcock M, et al: First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 23: 531-536, 2011.
18. Rietschel P, Wolchok JD, Krown S, et al: Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 26: 2299-2304, 2008.
19. Palmisano WA, Divine KK, Saccomanno G, et al: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958, 2000.
20. Kohonen-Corish MR, Cooper WA, Saab J, Thompson JF, Tren RJ and Millward MJ: Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J Invest Dermatol 126: 167-171, 2006. (Pubitemid 43336109)
21. Rastetter M, Schagdarsurengin U, Lahtz C, et al: Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histopathol 22: 1005-1015, 2007. (Pubitemid 47034166)
22. 6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol Cell Biol 11: 4660-4668, 1991.
23. Grombacher T, Mitra S and Kaina B: Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 17: 2329-2336, 1996. (Pubitemid 26402229)
24. Hassel JC, Sucker A, Edler L, et al: MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 103: 820-826, 2010.
25. Hamilton MG, Roldan G, Magliocco A, McIntyre JB, Parney I and Easaw JC: Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J Neurooncol 102: 255-260, 2011.
26. 6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 27: 388-390, 2008.